Antibody-drug conjugates have taken a back seat to cancer immunotherapy as the hot modality in oncology of late, but AbbVie Inc. and CytomX Therapeutics Inc. unveiled a partnership April 20 to develop an ADC targeting CD71 that the latter company is calling a further validation of its Probody technology platform.
AbbVie is paying $30m up front to co-develop and potentially co-commercialize a Probody-drug conjugate against CD71, also known as transferrin...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?